The DOI matches its Crossref record.
Epilepsy due to PNPO mutations: genotype, environment and treatment affect presentation and outcome
Open accessAbstract
The first described patients with pyridox(am)ine 5'-phosphate oxidase deficiency all had neonatal onset seizures that did not respond to treatment with pyridoxine but responded to treatment with pyridoxal 5'-phosphate. Our data suggest, however, that the clinical spectrum of pyridox(am)ine 5'-phosphate oxidase deficiency is much broader than has been reported in the literature. Sequencing of the PNPO gene was undertaken for a cohort of 82 individuals who had shown a reduction in frequency and severity of seizures in response to pyridoxine or pyridoxal 5'-phosphate. Novel sequence changes were studied using a new cell-free expression system and a mass spectrometry-based assay for pyridoxamine phosphate oxidase. Three groups of patients with PNPO mutations that had reduced enzyme activity were identified: (i) patients with neonatal onset seizures responding to pyridoxal 5'-phosphate (n = 6); (ii) a patient with infantile spasms (onset 5 months) responsive to pyridoxal 5'-phosphate (n = 1); and (iii) patients with seizures starting under 3 months of age responding to pyridoxine (n = 8). Data suggest that certain genotypes (R225H/C and D33V) are more likely to result in seizures that to respond to treatment with pyridoxine. Other mutations seem to be associated with infertility, miscarriage and prematurity. However, the situation is clearly complex with the same combination of mutations being seen in patients who responded and did not respond to pyridoxine. It is possible that pyridoxine responsiveness in PNPO deficiency is affected by prematurity and age at the time of the therapeutic trial. Other additional factors that are likely to influence treatment response and outcome include riboflavin status and how well the foetus has been supplied with vitamin B6 by the mother. For some patients there was a worsening of symptoms on changing from pyridoxine to pyridoxal 5'-phosphate. Many of the mutations in PNPO affected residues involved in binding flavin mononucleotide or pyridoxal 5'-phosphate and many of them showed residual enzyme activity. One sequence change (R116Q), predicted to affect flavin mononucleotide binding and binding of the two PNPO dimers, and with high residual activity was found in Groups (ii) and (iii). This sequence change has been reported in the 1000 Genomes project suggesting it could be a polymorphism but alternatively it could be a common mutation, perhaps responsible for the susceptibility locus for genetic generalized epilepsy on 17q21.32 (close to rs72823592). We believe the reduction in PNPO activity and B6-responsive epilepsy in the patients reported here indicates that it contributes to the pathogenesis of epilepsy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Zuberi, S. M., Wirrell, E., Yozawitz, E., Wilmshurst, J. M., Specchio, N., Riney, K., Pressler, R., Auvin, S., Samia, P., Hirsch, E., et al. (2022) · Epilepsia · doi:10.1111/epi.17239 · Cited by 934
Self-citationThe metabolic basis of epilepsy
Rho, J. M., & Boison, D. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-022-00651-8 · Cited by 295
Disorders affecting vitamin B6 metabolism
Wilson, M. P., Plecko, B., Mills, P. B., & Clayton, P. T. (2019) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12060 · Cited by 262
Self-citation
Metadata
- Authors
- Mills, P. B., Camuzeaux, S. S. M., Footitt, E. J., Mills, K. A., Gissen, P., Fisher, L., Das, K. B., Varadkar, S. M., Zuberi, S., McWilliam, R., Stodberg, T., Plecko, B., Baumgartner, M. R., Maier, O., Calvert, S., Riney, K., Wolf, N. I., Livingston, J. H., Bala, P., Morel, C. F., Feillet, F., Raimondi, F., Del Giudice, E., Chong, W. K., Pitt, M., & Clayton, P. T.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-03-18
- Volume
- 137
- Issue
- 5
- Pages
- 1350-1360
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2007527010
- Cited by
- 178
- References
- 0
- FWCI
- 11.71
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Epilepsy due to PNPO mutations: genotype, environment and treatment affect presentation and outcome. https://app.cochat.ai/papers/10.1093/brain/awu051
- The paper
- Mills, P. B., Camuzeaux, S. S. M., Footitt, E. J., Mills, K. A., Gissen, P., Fisher, L., Das, K. B., Varadkar, S. M., Zuberi, S., McWilliam, R., Stodberg, T., Plecko, B., Baumgartner, M. R., Maier, O., Calvert, S., Riney, K., Wolf, N. I., Livingston, J. H., Bala, P., . . . Clayton, P. T. (2014). Epilepsy due to PNPO mutations: genotype, environment and treatment affect presentation and outcome. Brain. https://doi.org/10.1093/brain/awu051
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.